The withdrawal of cisapride from the market will present challenges for phy
sicians treating patients with nocturnal heartburn, gastroparesis, and dysp
epsia. However, alternatives to the drug exist, and it will continue to be
available under a limited-access program for patients for whom other drug t
reatments fail.